ARPA-H opens first interventional clinical trials to outpace cancer in real time

ARPA-H launches program to supercharge biosensor device development with next-gen platform

The Advanced Research Projects Agency for Health, an agency within HHS, announced the launch of its Delphi program, an initiative to advance low-cost biosensors that can monitor hormones, inflammatory markers, and other important biochemical signals.

March 13, 2026

Clinical Roundup

Combination treatment may dramatically improve survival in brain cancer

A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.

March 06, 2026

Vol.52 No.09

Guest Editorial

When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need

Radiology departments have tried for years to “own” or “fix” clinical trials imaging assessment workflows by extending clinical tools (PACS, worklists, dictation systems) and habits (speed, seamlessness, few clicks) into the research world.

ARPA-H announces team awards focused on longevity research

The Advanced Research Projects Agency for Health, an agency within HHS, announced the seven research teams across the United States funded through its PROactive Solutions for Prolonging Resilience program.

February 27, 2026

Vol.52 No.08

Clinical Roundup

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

High-level results from the randomized, controlled NHS-Galleri trial, which is evaluating GRAIL’s multi-cancer screening test, Galleri, over three years in 142,000 participants aged 50 to 77, reveals that the trial did not meet its primary endpoint of shifting cancer diagnosis from advanced stages (3 and 4) to earlier stage (1 and 2).

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Results from the phase I/II multicenter international CADENZA trial, led by researchers at the University of Texas MD Anderson Cancer Center, show that 75% of patients with blastic plasmacytoid dendritic cell neoplasm who were treated with the antibody-drug conjugate pivekimab sunirine had a complete response.

February 20, 2026

Vol.52 No.07

ARPA-H opens first interventional clinical trials to outpace cancer in real time

YOU MAY BE INTERESTED IN

ARPA-H launches program to supercharge biosensor device development with next-gen platform

Combination treatment may dramatically improve survival in brain cancer

When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need

ARPA-H announces team awards focused on longevity research

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Renew today!

Subscriber content

Never miss an issue!

Login

ARPA-H opens first interventional clinical trials to outpace cancer in real time

YOU MAY BE INTERESTED IN

ARPA-H launches program to supercharge biosensor device development with next-gen platform

Combination treatment may dramatically improve survival in brain cancer

When radiology fails to fix clinical trial imaging workflow at sites…What most think, why it’s wrong, and what cancer centers really need

ARPA-H announces team awards focused on longevity research

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Never miss an issue!

Login

When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need